ClinicalTrials.gg
Active, not recruitingNCT05211895PACIFIC-8Updated Aug 28, 2026

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

A Phase 3 interventional study of Durvalumab and Domvanalimab in Non-Small Cell Lung Cancer, sponsored by AstraZeneca. Active, not recruiting at 226 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
791
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca — 26 open to participants now, 79 under way, 28 of them phase 3. Carcinoma, Non-Small-Cell Lung · AstraZeneca.

Enrollment
15th of 138
791 · median 153
Started
2022
with 13 others
Phase 3
44 of 210
6 open now
Primary completion
2026-08
later than 34 of 78 live
Registered
154th of 210
by date

Among the 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 15th largest by enrollment of the 138 interventional ones that give a count, is one of 14 that started in 2022, is one of 44 in phase 3, reaches primary completion later than 34 of the 78 other live ones, and was the 154th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

26 of the 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 26 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, or all of them as a file.
02

Study summary

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • non-small cell lung cancer
  • locally advanced
  • NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be ≥ 18 years at the time of screening.
  2. - or cytologically-documented NSCLC and have been treated with concurrent CRT for locally advanced, unresectable (Stage III) disease
  3. Provision of a tumour tissue sample obtained prior to CRT
  4. Documented tumour status ≥ 1% by central lab
  5. Documented EGFR and ALK wild-type status (local or central).
  6. Patients must not have progressed following definitive, platinum-based, concurrent chemoradiotherapy
  7. Participants must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy
  8. Participants must have received a total dose of radiation of 60 Gy ±10% (54 Gy to 66 Gy) as part of the chemoradiation therapy, to be randomised. Radiation therapy should be administered by intensity modulated RT (preferred) or 3D-conforming technique.
  9. of 0 or 1 at randomization
  10. Adequate organ and marrow function

Exclusion criteria

EXCLUSION CRITERIA:

  1. History of another primary , except for:

    • Malignancies treated with curative intent and adequate follow-up with no known active disease and have not required active treatment within the past 3 years before the first dose of study intervention and of low potential risk of recurrence.
    • Adequately resected non melanoma skin cancer or lentigo maligna without evidence of disease .
    • Adequately treated carcinoma in situ, including Ta tumors without evidence of disease.
  2. Mixed small cell and non-small cell lung cancer histology.
  3. Participants who receive sequential (not inclusive of induction) chemoradiation therapy for locally advanced (Stage III) unresectable NSCLC.
  4. Participants with locally advanced (Stage III) unresectable NSCLC who have progressed during platinum-based cCRT.
  5. Any unresolved toxicity >Grade 2 from the prior chemoradiation therapy (excluding alopecia).
  6. Participants with ≥ grade 2 pneumonitis from prior chemoradiation therapy.
  7. History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, or idiopathic pneumonitis - regardless of time of onset prior to randomisation. Evidence of active non-CRT induced pneumonitis (≥ Grade 2), active pneumonia, active ILD, active or recently treated pleural effusion, or current pulmonary fibrosis
  8. Active or prior documented or inflammatory disorders (with exceptions)
  9. Active EBV infection, or known or suspected chronic active EBV infection at screening
  10. Current or prior use of medication within 14 days before the first dose of durvalumab.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
791 participants (actual)

Study arms

  • Experimental
    Arm A: Durvalumab + Domvanalimab

    Durvalumab and domvanalimab as an IV infusion q4w, starting on Day 1 for up to a maximum of 12 months

    Drug: Durvalumab · Drug: Domvanalimab

  • Active comparator
    Arm B: Durvalumab + Placebo

    Durvalumab + placebo as an IV infusion q4w starting on Day 1 for up to a maximum of 12 months

    Drug: Durvalumab · Other: Placebo

Interventions

  • Durvalumab IV (Intravenous infusion)

  • Domvanalimab IV (Intravenous infusion)

  • OtherPlacebo

    Placebo IV (Intravenous infusion)

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    Defined as time from randomisation until progression per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR), or death due to any cause in participants with PD-L1 TC ≥ 50%. Outcomes measures were applicable with the previous version of the protocol. The study objectives are considered descriptive rather than confirmatory according to the protocol amendment.

    Time frame: Up to 5 years after randomization

Secondary outcomes

  1. Progression Free Survival (PFS)

    Defined as time from randomisation until progression per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR), or death due to any cause in participants with PD-L1 TC ≥ 1% Outcomes measures were applicable with the previous version of the protocol. The study objectives are considered descriptive rather than confirmatory according to the protocol amendment.

    Time frame: Up to 5 years after randomization

  2. Overall Survival (OS)

    Overall Survival (OS) Outcomes measures were applicable with the previous version of the protocol. The study objectives are considered descriptive rather than confirmatory according to the protocol amendment.

    Time frame: Approximately 5 years after randomization

  3. Objective Response Rate (ORR)

    Objective Response Rate (ORR) per RECIST 1.1 as assessed by BICR Outcomes measures were applicable with the previous version of the protocol. The study objectives are considered descriptive rather than confirmatory according to the protocol amendment.

    Time frame: Approximately 5 years after randomization

  4. Duration of Response (DoR)

    Duration of Response (DoR) using BICR assessment according to RECIST 1.1 Outcomes measures were applicable with the previous version of the protocol. The study objectives are considered descriptive rather than confirmatory according to the protocol amendment.

    Time frame: Approximately 5 years after randomization

  5. Time from randomization to second progression (PFS2)

    Time from randomization to second progression (PFS2) Outcomes measures were applicable with the previous version of the protocol. The study objectives are considered descriptive rather than confirmatory according to the protocol amendment.

    Time frame: Approximately 5 years after randomization

  6. Time from randomization to first date of distant metastasis or death (TTDM)

    Time from randomization until the first date of distant metastasis or death in the absence of distant metastasis (TTDM). Outcomes measures were applicable with the previous version of the protocol. The study objectives are considered descriptive rather than confirmatory according to the protocol amendment.

    Time frame: Approximately 5 years after randomization

  7. Time to first subsequent therapy (TFST)

    Time to first subsequent therapy (TFST) Outcomes measures were applicable with the previous version of the protocol. The study objectives are considered descriptive rather than confirmatory according to the protocol amendment.

    Time frame: Approximately 5 years after randomization

  8. Concentration of Durvalumab and Domvanalimab

    The pharmacokinetics (PK) of Durvalumab and Domvanalimab as determined by concentration Outcomes measures were applicable with the previous version of the protocol. The study objectives are considered descriptive rather than confirmatory according to the protocol amendment.

    Time frame: Approximately 12 weeks after last IP dose

  9. PFS6, PFS12, PFS18, PFS24

    PFS at 6, 12, 18 and 24 months (proportion per Kaplan-Meier) Outcomes measures were applicable with the previous version of the protocol. The study objectives are considered descriptive rather than confirmatory according to the protocol amendment.

    Time frame: Approximately 6, 12, 18 and 24 months after randomization

  10. Anti-Drug Antibodies (ADAs)

    The immunogenicity of Durvalumab and domvanalimab as assessed by presence of Anti-Drug Antibodies (ADAs) Outcomes measures were applicable with the previous version of the protocol. The study objectives are considered descriptive rather than confirmatory according to the protocol amendment.

    Time frame: Approximately 12 weeks after last IP dose.

  11. Time to deterioration in pulmonary symptoms (TTFCD)

    Time to deterioration in pulmonary symptoms (TTFCD) Outcomes measures were applicable with the previous version of the protocol. The study objectives are considered descriptive rather than confirmatory according to the protocol amendment.

    Time frame: Approximately 5 years after randomization

  12. PFS investigator

    Defined as time from randomisation until progression per RECIST 1.1 as assessed by Investigator or death due to any cause in participants Outcomes measures were applicable with the previous version of the protocol. The study objectives are considered descriptive rather than confirmatory according to the protocol amendment.

    Time frame: Up to 5 years after randomization

  13. OS 24

    Overall Survival (OS) at 24 months Outcomes measures were applicable with the previous version of the protocol. The study objectives are considered descriptive rather than confirmatory according to the protocol amendment.

    Time frame: Approximately 24 months after randomization

07

Study locations

226 sites
  • Research Site
    Chandler, Arizona 85224, United States
  • Research Site
    Phoenix, Arizona 85054, United States
  • Research Site
    Fountain Valley, California 92708, United States
  • Research Site
    Santa Rosa, California 95403, United States
  • Research Site
    Washington D.C., District of Columbia 20016, United States
  • Research Site
    Jacksonville, Florida 32224, United States
  • Research Site
    Orlando, Florida 32804, United States
  • Research Site
    Saint Augustine, Florida 32086, United States
  • Research Site
    Macon, Georgia 31217, United States
  • Research Site
    Elmhurst, Illinois 60126, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    Baltimore, Maryland 21224, United States
  • Research Site
    Silver Spring, Maryland 20910, United States
  • Research Site
    Ann Arbor, Michigan 48106-0995, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Minneapolis, Minnesota 55407, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Reno, Nevada 89511, United States
  • Research Site
    East Brunswick, New Jersey 08816, United States
  • Research Site
    Columbus, Ohio 43214, United States
  • Research Site
    Maumee, Ohio 43537, United States
  • Research Site
    Oklahoma City, Oklahoma 73102, United States
  • Research Site
    Pittsburgh, Pennsylvania 15212, United States
  • Research Site
    Charleston, South Carolina 29401, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    Fort Sam Houston, Texas 78234, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Fort Belvoir, Virginia 22060, United States
  • Research Site
    Spokane Valley, Washington 99216, United States
  • Research Site
    Appleton, Wisconsin 54911, United States
  • Research Site
    Brussels, 1160, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Haine-Saint-Paul, 7100, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Sint-Niklaas, 9100, Belgium
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Londrina, 86015-520, Brazil
  • Research Site
    Porto Alegre, 91350200, Brazil
  • Research Site
    Porto Velho, 76834-899, Brazil
  • Research Site
    Rio de Janeiro, 20231-050, Brazil
  • Research Site
    Santo André, 09060-650, Brazil
  • Research Site
    São Paulo, 01221-900, Brazil
  • Research Site
    Taubaté, 12030-200, Brazil
  • Research Site
    Calgary, Alberta T2N 5G2, Canada
  • Research Site
    Kelowna, British Columbia V1Y 5L3, Canada
  • Research Site
    Laval, Quebec H7M 3L9, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Las Condes, 7560908, Chile
  • Research Site
    Port Montt, 5500243, Chile
  • Research Site
    Santiago, 7500713, Chile
  • Research Site
    Santiago, 7520426, Chile
  • Research Site
    Santiago, 7630370, Chile
  • Research Site
    Santiago, 8241479, Chile
  • Research Site
    Temuco, 4810218, Chile
  • Research Site
    Aix-en-Provence, 13616, France
  • Research Site
    Angers, 49055, France
  • Research Site
    Bobigny, 93000, France
  • Research Site
    Lille, 59000, France
  • Research Site
    Paris, 75014, France
  • Research Site
    Pau, 6400, France
  • Research Site
    Quimper, 29000, France
  • Research Site
    Saint-Grégoire, 35760, France
  • Research Site
    Saint-Quentin, 02321, France
  • Research Site
    Vantoux, 57070, France
  • Research Site
    Villeurbanne, 69100, France
  • Research Site
    Berlin, 12351, Germany
  • Research Site
    Berlin-Zehlendorf, 14165, Germany
  • Research Site
    Braunschweig, 38114, Germany
  • Research Site
    Chemnitz, 09116, Germany
  • Research Site
    Cologne, 51109, Germany
  • Research Site
    Erlangen, 91054, Germany
  • Research Site
    Essen, 45147, Germany
  • Research Site
    Giessen, 35392, Germany
  • Research Site
    Halle, 06120, Germany
  • Research Site
    Koblenz, 56073, Germany
  • Research Site
    Krefeld, 47805, Germany
  • Research Site
    Löwenstein, 74245, Germany
  • Research Site
    Moers, 47441, Germany
  • Research Site
    Regensburg, 93049, Germany
  • Research Site
    Regensburg, 93053, Germany
  • Research Site
    Tübingen, 72076, Germany
  • Research Site
    Athens, 11526, Greece
  • Research Site
    Athens, 11527, Greece
  • Research Site
    Athens, 12462, Greece
  • Research Site
    Athens, 18547, Greece
  • Research Site
    Holargos, Athens, 155 62, Greece
  • Research Site
    Thessaloniki, 55236, Greece
  • Research Site
    Thessaloniki, 56 429, Greece
  • Research Site
    Thessaloniki, 57001, Greece
  • Research Site
    Hong Kong, 150001, Hong Kong
  • Research Site
    Budapest, 1121, Hungary
  • Research Site
    Budapest, 1122, Hungary
  • Research Site
    Deszk, 6772, Hungary
  • Research Site
    Győr, 9024, Hungary
  • Research Site
    Salgótarján, 3100, Hungary
  • Research Site
    Székesfehérvár, 8000, Hungary
  • Research Site
    Törökbálint, 2045, Hungary

Showing the first 100 of 226 sites across 28 countries. Choose a country and city above to see the rest.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Aug 2026, 53 months.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 53 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2022
First posted
Jan 27, 2022
StartActual
Feb 18, 2022
Primary completionActual
Aug 10, 2026
CompletionEst.
Sep 8, 2027
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05211895
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 27, 2022
Start date
Feb 18, 2022
Primary completion
Aug 10, 2026
Completion
Sep 8, 2027 (estimated)
Last update
Aug 28, 2026

Study contacts

Hidehito Horinouchi, MD, PhD
principal investigator · National Cancer Center Hospital
Alexander Spira, MD, PhD
principal investigator · Virginia Cancer Specialists Research Institute
Jinming Yu, MD, PhD
principal investigator · Shandong Cancer Hospital and Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Domvanalimab

Start the discussion